Overview
Casts new light on liquid biopsy biomarkers for cancer screening
Equips readers to treat molecular targeting therapy positively
Maximizes reader insights into cancer screening and early diagnosis
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (14 chapters)
-
Front Matter
-
Various Strategies to Detect Cancer
-
Front Matter
-
-
Biomarkers for Individual Cancers
-
Front Matter
-
Keywords
About this book
This book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers – all of which serve as the basis for exploring key research questions for future clinical trials in the book’s second half.
The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy.The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.
Editors and Affiliations
About the editor
In the course of his career, he has served on numerous committees for national and international societies regarding cancer treatment, surgery and biomarkers. His current area of interest is in cancer biomarkers, specifically in gastroenterological cancer.
The author of the recent Japanese Molecular Tumor Marker Guideline, and of the Japanese Gastric Cancer Treatment Guideline, Dr. Shimada also serves as an editor for various international journals, e.g. Cancer Science, Ann Gastroenterological Surgery, Esophagus, Gastric Cancer, Ann Thoracic Cardiovascular Surgery, Digestive Surgery, and Surgery Today. In 2016 he received the JSGS (Japanese Society of Gastroenterological Surgery) Scientist of the Year Award.
Bibliographic Information
Book Title: Biomarkers in Cancer Therapy
Book Subtitle: Liquid Biopsy Comes of Age
Editors: Hideaki Shimada
DOI: https://doi.org/10.1007/978-981-13-7295-7
Publisher: Springer Singapore
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Nature Singapore Pte Ltd. 2019
Hardcover ISBN: 978-981-13-7294-0Published: 05 July 2019
Softcover ISBN: 978-981-13-7297-1Published: 15 August 2020
eBook ISBN: 978-981-13-7295-7Published: 30 May 2019
Edition Number: 1
Number of Pages: VIII, 157
Number of Illustrations: 5 b/w illustrations, 17 illustrations in colour
Topics: Oncology, Cancer Research